RASAGILINE Drug Patent Profile
When do Rasagiline patents expire, and when can generic versions of Rasagiline launch?
Rasagiline is a drug marketed by Alkem Labs Ltd, Apotex Inc, Aurobindo Pharma Usa, Carnegie, Chartwell Rx, Macleods Pharms, Micro Labs, Orbion Pharms, Regcon Holdings, Rising, Torrent, and Watson Labs Inc. and is included in twelve NDAs.
The generic ingredient in RASAGILINE is rasagiline mesylate. There is one drug master file entry for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the rasagiline mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rasagiline
A generic version of RASAGILINE was approved as rasagiline mesylate by ORBION PHARMS on March 15th, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RASAGILINE?
- What are the global sales for RASAGILINE?
- What is Average Wholesale Price for RASAGILINE?
Summary for RASAGILINE
| US Patents: | 0 |
| Applicants: | 12 |
| NDAs: | 12 |
| Drug Prices: | Drug price information for RASAGILINE |
| What excipients (inactive ingredients) are in RASAGILINE? | RASAGILINE excipients list |
| DailyMed Link: | RASAGILINE at DailyMed |
Recent Clinical Trials for RASAGILINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Guangzhou Henovcom Bioscience Co. Ltd. | PHASE1 |
| Guizhou Medical University | Phase 2/Phase 3 |
| The First Affiliated Hospital of Dalian Medical University | Phase 2/Phase 3 |


